Debiopharm Takes a Step Forward for Children With CPP: Enrollment Completion for the Phase III Trial Evaluating the First Ever Yearly Injectable Triptorelin Formulation

Contributed by: Business Wire

Logo

Tags

Children

Biotechnology

Health

Pharmaceutical

Oncology

Other Science

Research

Family

Consumer

Science

Clinical Trials

Debiopharm

More Like This

First Patients Dosed in Debiopharm's Phase III Trial (LIBELULA) Investigating Debio 4326, a 12-Month Triptorelin Formulation for Children with Central Precocious Puberty

Redefining Acromegaly Care: First Patient Randomized in Debiopharm’s Phase III OXTEND-03™ Trial of 3-Month Debio 4126 Treatment

Debiopharm Pushes the Boundaries of Innovation in Antibiotic Development Against Gonorrhea with First-In-Human Debio 1453 Trial

Debiopharm Ignites Oncology Innovation With Clinical and Translational Data on Debio 0123 at the 2025 ASCO Annual Meeting in Chicago

Debiopharm & Repare Therapeutics Announce First Patient Dosed in Phase 1/1b Mythic Trial Evaluating the Synthetic Lethal Combination of WEE1 AND PKMYT1 Inhibition

MEDSIR & Debiopharm Announce the First Patient Dosed in the WIN-B Trial Exploring the Combination of Debio 0123 & Gilead’s Trodelvy® in Advanced Breast Cancer

Following Oral Presentation of Phase I Data at AACR 2026, Debiopharm Announces FDA Fast Track Designation for Lunresertib in Combination With Zedoresertib for Genomic-Defined Platinum-Resistant Ovarian Cancer

Debiopharm to Reveal Insights From Their ADC, DDR Inhibitor, and Antibody Conjugation Technology Research at the 2025 AACR Conference in Chicago